Skip to content

Zymeworks ZYME Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Septerna, Inc. logo
Septerna, Inc.SEPN
Charles River Laboratories logo
Charles River LaboratoriesCRL
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's contract liabilities, non-current?
Zymeworks (ZYME) reported contract liabilities, non-current of $14.61M in Q1 2026.
How has Zymeworks's contract liabilities, non-current changed year-over-year?
Zymeworks's contract liabilities, non-current decreased by 0.0% year-over-year, from $14.61M to $14.61M.
What is the long-term trend for Zymeworks's contract liabilities, non-current?
Over 4 years (2021 to 2025), Zymeworks's contract liabilities, non-current has grown at a -18.4% compound annual growth rate (CAGR), from $32.94M to $14.61M.